Injection of a Jagged1 inhibitor (such as an anti-Jagged1 monoclonal antibody, here 15D11) in mice improved the chemosensitivity of cancer cells, making it a promising candidate for targeting the bone microenvironment (38). This evidence concerns the gene JAG1 and cancer.